Shareholding disclosure

GEFIM SPA

Declared position

15.9%

Threshold

Crossed upwards

Timeline

Published

27.09.2012

Transaction

24.09.2012

Voting rights breakdown

Voting rights acquired15.9%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAC9Q00023

Beneficial owner

GEFIM SPA

Declared address

GEFIM SPA, 20122 MILANO

dissolution of a group created on 19 September 2012 and dissolved on 24 September 2012 Zambon is an entity controlled for the 85.92% by GEFIM. Dolphin SpA is a wholly owned subsidiary of Zambon,

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

GEFIM SPA

Newron Pharmaceuticals S.p.A.27.09.2012TAC9Q00023

Disclosure summary

GEFIM SPA disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 27.09.2012, at 15.9% of voting rights. Notice category: Single shareholder.

Disclosed position

15.9%

Voting rights acquired

Voting rights acquired15.9%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

GEFIM SPA disclosed a holding in Newron Pharmaceuticals S.p.A., published on 27.09.2012.

Publication date27.09.2012

Transaction date24.09.2012

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerGEFIM SPA

Declared addressGEFIM SPA, 20122 MILANO

CategorySingle shareholder

Voting rights acquired15.9%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAC9Q00023

Conditions

dissolution of a group created on 19 September 2012 and dissolved on 24 September 2012 Zambon is an entity controlled for the 85.92% by GEFIM. Dolphin SpA is a wholly owned subsidiary of Zambon,

Source: SIX Exchange Regulation · Publication date: 27.09.2012

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open